AstraZeneca to manufacture cancer killer in Singapore

By : Xinhua

Date: 20 May 2024 10:22am WAT

(FILES) In this file photo taken on July 21, 2020 a general view is pictured of the offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, Cheshire. Pharmaceutical company AstraZeneca said on September 8, 2020 that it had "voluntarily paused" a randomized clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness. Paul ELLIS / AFP

AstraZeneca says it will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs).

The biopharmaceutical giant announced on Monday.

AstraZeneca aimed to start designing and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.

According to the company ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.